BioNTech, Pfizer ask Europe to OK vaccine for emergency use
Germany's BioNTech and its US partner Pfizer on Tuesday said they had applied for EU regulatory approval for their Covid-19 vaccine, raising hopes that the first jabs could be administered in December. The two companies said in a statement that they had submitted an application to the European Medicines Agency on Monday for their vaccine.
- World
- AP
- Published Date: 01:32 | 01 December 2020
- Modified Date: 01:36 | 01 December 2020
German pharmaceutical company BioNTech and its U.S. partner Pfizer say they have submitted an application for conditional approval of their coronavirus vaccine with the European Medicines Agency.
The two companies said Tuesday that the submission, which occurred Monday, completes the rolling review process they initiated with the agency on Oct. 6.
The move comes a day after rival Moderna said it was asking U.S. and European regulators to allow emergency use of its COVID-19 vaccine.
BioNTech said that if the vaccine, currently named BNT162b2, is approved, its use in Europe could begin before the end of 2020.
- House seen backing bill that could block Chinese firms from U.S. securities markets
- Florida 3rd US state to hit 1 million coronavirus cases
- Brazil registers 697 new COVID-19 deaths as cases surge
- Trump to meet next week with industry, government officials on COVID vaccine
- Madrid region inaugurates COVID-19 hospital, unions protest lack of staff